Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation

Nancy L. Bartlett , Andy I. Chen , Kathryn S. Kolibaba , Thierry Lamy (1, 2) , Surai Jones , Jamie Hirata , Jeff P Sharman

1 CHU Pontchaillou [Rennes]
2 MiCa - Microenvironnement et cancer

Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015

Domains: Life Sciences [q-bio]

Nancy L. Bartlett, Andy I. Chen, Kathryn S. Kolibaba, Thierry Lamy, Surai Jones, et al.. Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation. Blood, 2015, 126 (23), pp.2726. ⟨hal-01290426⟩